Drug-Eluting Stent for Unprotected Left Main Coronary Artery Disease: Early and Mid-Term Outcomes
Worawut Tassanawiwat MD*, Weera Mahavanakul MD*, Praprut Thanakitcharu MD*, Piyarat Komolsart MD*, Sopida Chansod RN*, Bancha Sookananchai MD**, Chaiyasith Wongvipaporn MD***, Songsak Kiatchoosakun MD***, Sakda Cheiniwat MD****, Damras Tresukosol MD*****
Affiliation : * Sappasitthiprasong Hospital, Ubonratchathani, Thailand ** Maharat Nakhon Ratchasima Hospital, Nakhon Ratchasima, Thailand *** Division of Cardiology, Medicine, Khon Kaen University, Khon Kaen, Thailand **** Saint Louis Hospital, Bangkok, Thailand ***** Division of Cardiology, Medicine, Her Majesty’s Cardiac Center, Siriraj Hospital, Bangkok, Thailand
Background : PCI is increasingly performed in patients with ULMCA disease. The efficacy and safety of drug-eluting stents
in ULMCA disease have been reported.
Objective : To evaluate the early and mid-term clinical outcome of the Percutaneous Coronary Intervention (PCI) with Drug-
Eluting stent (DES) in unprotected left main coronary artery (ULMCA) disease patients.
Material and Method: PCI with DES was performed with 90 consecutive patients having ULMCA disease between January
2006 and June 2009.
Results : At a median follow-up of 22.8 + 12.2 months, major adverse cardiac or cerebrovascular events (MACCE) occurred
in 11 (12.2%) patients. There were seven (7.8%) deaths including two (2.2%) cardiac deaths and five (5.6%) non-cardiac
deaths. There was one MI (1.1%), and four (4.4%) target vessel revascularization. Restenosis in the left main occurred only
in two patients (2.2%) and definite stent thrombosis occurred in two patients (2.2%).
Conclusion : The present study demonstrates that PCI with Drug-Eluting stent implantation in unprotected left main coronary
artery disease is a safe form of treatment and has favorable outcomes.
Keywords : Left main, Drug Eluting stent
